Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

UGN-104

Small molecule · Cytotoxic · developed by UroGen Pharma

Phase 3 Most advanced trial
URGN Developer
1 Registered trials

What is UGN-104?

UGN-104 is a formulation of mitomycin reconstituted with a sterile, thermally responsive hydrogel. It is liquid when chilled and converts to a semi-solid gel depot after instillation into the upper urinary tract, providing local delivery of mitomycin. It is studied in upper urinary tract urothelial carcinoma and urothelial carcinoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Mechanism
Cytotoxic
Therapy area
Oncology
Developer
UroGen Pharma Ltd. (URGN)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06774131 Phase 3 Upper Urinary Tract Urothelial Carcinoma Recruiting URGN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Upper Urinary Tract Urothelial CarcinomaUrothelial Carcinoma

More from UroGen Pharma

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the URGN page.

Follow URGN, the company behind UGN-104

See URGN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

URGN catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.